How to rescue a DreaMM deferred ….

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-09-13 DOI:10.1016/j.medj.2024.07.027

Nisha S Joseph, Sagar Lonial

引用次数: 0

Abstract

The recently published DreaMM-7 and -8 trials¹^,² demonstrate the benefit of triplet combination regimens including the anti-BCMA antibody drug conjugate belantamab mafodotin. Here, we describe the findings of these trials including efficacy and safety data and provide commentary on the implications for future use of belantamab in the relapsed myeloma space.

查看原文本刊更多论文

如何挽救 DreaMM 延期的 ....

最近发表的DreaMM-7和-8试验1,2证明了包括抗BCMA抗体药物共轭物贝仑单抗马福多汀在内的三联疗法的益处。在此，我们将介绍这些试验的结果，包括疗效和安全性数据，并就贝仑单抗未来在复发性骨髓瘤领域的应用提供评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.